Abstract

[Problem] To provide a phosphorus-based flame retardant having excellent post-washing durability in addition to having initial flame retardancy. [Solution] The present invention pertains to: a phosphorus-containing (meth)acrylic polymer containing, as (meth)acrylic monomers (A), one or more specific phosphorus-based compounds; and a fiber flame retardant containing the same.

IPC Classes  ?

• C08F 20/26 - Esters containing oxygen in addition to the carboxy oxygen
• C09K 21/12 - Organic materials containing phosphorus
• D06M 15/263 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds of unsaturated carboxylic acidsSalts or esters thereof

Abstract

This cell culture kit (100) is provided with a culture vessel (110), a spacer (130), and a lid (150). The culture vessel (110) has therein a culture space (111) for culturing cells, and includes an opening (114a) that communicates with the culture space (111). The spacer (130) is a cylinder with an open top and bottom, and is removably stored in the culture space (111). The lid (150) can be placed on the spacer (130). The spacer (130) is taller than the culture space (111).

IPC Classes  ?

• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• C12N 5/04 - Plant cells or tissues
• C12N 5/07 - Animal cells or tissues

Abstract

The present invention addresses the problem of preparing an enzymatic reaction solution by extracting an enzyme contained in a bacterium or yeast in such a state where the enzyme retains the enzymatic activity thereof without subjecting the bacterium or yeast to a pulverization treatment or a lytic treatment.　Provided is a method for preparing an enzymatic reaction solution by extracting a specific enzyme from a bacterium or yeast expressing the enzyme in such a state where the enzyme retains the enzymatic activity thereof, the method including a step in which the bacterium or yeast is treated at 4-95°C for 0.1 hour to 4 days with a 0.05-1.0 M buffer solution that contains 0-3% of a nonionic surfactant or a bipolar surfactant and is an enzyme extraction solution adjusted to pH 6-11. The method does not include a step for pulverizing the bacterium or yeast or a step for lysing the bacterium or yeast.

IPC Classes  ?

• C12P 1/00 - Preparation of compounds or compositions, not provided for in groups , by using microorganisms or enzymesGeneral processes for the preparation of compounds or compositions by using microorganisms or enzymes
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 15/54 - Transferases (2)

Abstract

The present invention addresses the problem of providing a novel method for synthesizing a deoxynucleoside triphosphate or nucleoside triphosphate.　This method for synthesizing a deoxynucleoside triphosphate (dNTP) from a deoxyribonucleoside or synthesizing a ribonucleoside triphosphate (NTP) from a ribonucleoside is characterized by: adding, to a reaction vessel, (i) a deoxyribonucleoside or ribonucleoside as a starting material, (ii) a kinase capable of producing a deoxyribonucleoside monophosphate from the deoxyribonucleoside or a ribonucleoside monophosphate from the ribonucleoside, a kinase capable of producing a deoxyribonucleoside diphosphate from the deoxyribonucleoside monophosphate or a ribonucleoside diphosphate from the ribonucleoside monophosphate, and a pyruvate kinase as enzymes, and (iii) a nucleoside triphosphate or deoxynucleoside triphosphate and a phosphoenolpyruvic acid (PEP) as phosphoric acid donors, thereby adjusting a reaction solution; and reacting the same in one pot.

IPC Classes  ?

• C12P 19/32 - Nucleotides having a condensed ring system containing a six-membered ring having two nitrogen atoms in the same-ring, e.g. purine nucleotides, nicotineamide-adenine dinucleotide
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 15/54 - Transferases (2)

Abstract

A frozen product of a three-dimensional cell culture according to the present invention comprises: a three-dimensional cell culture having a cell-to-cell connection structure; and a cryopreservation liquid. The cryopreservation liquid contains a calcium salt and water, wherein the content of the calcium salt is 3.5 ppm to 500 ppm (both inclusive) in terms of calcium ion on the basis of the total weight of the cryopreservation liquid.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12N 1/04 - Preserving or maintaining viable microorganisms
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells

Abstract

There are disclosed an ultraviolet irradiation device and an ultraviolet irradiation method that can easily and appropriately decompose biofilms. The ultraviolet light irradiation device includes a light source part having a light source that emits ultraviolet light in a wavelength range of 190 nm to 240 nm, and a supporting part supporting the light source part to cause the ultraviolet light emitted from the light source to be applied onto a biofilm. The ultraviolet irradiation decomposes the biofilm by irradiating the biofilm with the ultraviolet light.

IPC Classes  ?

• A61L 2/00 - Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lensesAccessories therefor
• A61N 5/06 - Radiation therapy using light

Abstract

The present invention addresses the problem of providing a novel method capable of diagnosing advanced adenoma in the large intestine, or a novel method capable of diagnosing either advanced adenoma in the large intestine or colorectal cancer.　As one aspect, provided is a method for assisting the diagnosis of advanced adenoma in the large intestine in a subject, the method including (i) a step A for measuring a methylation level of CpG present in a region lying from +1 to +300 of a transcription start point in a somatostatin (SST) gene in DNA extracted from feces collected from the subject, (ii) a step B for measuring a quantitative level of a specific internal control gene in the DNA extracted from feces collected from the subject, and (iii) a step C for calculating a corrected methylation level by correcting the methylation level of CpG in the SST gene which has been measured in step A by the quantitative level of the specific internal control gene which has been measured in step B, wherein the assistance of the diagnosis is performed by comparing the corrected methylation level which has been calculated in step C with a predetermined cut-off value.

IPC Classes  ?

• C12Q 1/6851 - Quantitative amplification
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms

Abstract

The present invention simultaneously identifies genetic mutations in MYD88 and/or genetic mutations in CD79B.　The present invention comprises: a primer set for MYD88 gene mutations and a primer set for CD79B gene mutations; and a mutant probe for the MYD88 gene together with a wild-type probe for the MYD88 gene, and a mutant probe for the CD79B gene together with a wild-type probe for the CD79B gene.

IPC Classes  ?

• C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
• C12N 15/09 - Recombinant DNA-technology

Abstract

The present invention addresses the problem of providing a new prophylactic or therapeutic agent for a kidney diseases. Provided is a prophylactic or therapeutic agent for polycystic kidney disease, the agent comprising, as an active ingredient, a compound that promotes intermolecular interaction between an oxysterol-binding protein-related protein-3 (ORP3) and an endoplasmic vesicle protein-associated protein-A (VAP-A) in a cell, and has a cholesterol increasing effect in primary cilia of the cell, or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 31/18 - Sulfonamides
• A61K 31/4035 - Isoindoles, e.g. phthalimide
• A61K 31/426 - 1,3-Thiazoles
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

It is an object of the present invention to provide a drug for preventing or treating a liver disease associated with fibrosis, the drug containing microRNAs as an active ingredient. A pharmaceutical composition for preventing or treating a liver disease associated with fibrosis, the pharmaceutical composition containing at least one kind of microRNAs selected from miR 1237-5p, miR 204-3p, miR 7977, miR 6089, and miR 5787 as an active ingredient, is produced.

IPC Classes  ?

• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

The purpose of the present invention is to provide a new method that makes it possible to diagnose hepatocellular carcinoma, especially early-stage hepatocellular carcinoma, with high sensitivity, on the basis of new factors instead of AFP or PIVKA-II, and without requiring genetic testing.　The method for examining the possibility that a subject contracts hepatocellular carcinoma includes measuring (a) or (b) in a blood sample isolated from a subject, where (a) is a glycated ferritin amount and the total ferritin amount and (b) is the ratio of the glycated ferritin to the amount of total ferritin or non-glycated ferritin.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

[Problem] To provide: a method for identifying a new depression marker and assisting determination of depression on the basis of the depression marker; and diagnosis kit for depression based on the depression marker. [Solution] This method for assisting the determination of depression is characterized by including a step for measuring the amount of von Willebrand factor present in extracellular vesicles in a biological sample collected from a subject and comparing the measured amount with a predetermined value.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

The present invention addresses the problem of providing a method capable of effectively regulating the growth of a plant. The growth of a plant can be effectively regulated by this method comprising: (A) a step for growing the plant in the presence of hematite; and (B) a step for growing the plant in substantially the absence of hematite.

IPC Classes  ?

• A01G 7/00 - Botany in general
• A01G 24/10 - Growth substratesCulture mediaApparatus or methods therefor based on or containing inorganic material
• A01P 21/00 - Plant growth regulators

Abstract

The present invention addresses the problem of providing: a method for relatively easily and accurately determining colon cancer at an early stage; and a kit or the like used for the determination.　In the present invention, whether or not a subject suffers from colon cancer is determined using, as an index, the methylation level of a CpG site in the promoter region of the LINC01869 gene and/or the expression level of a transcript of the LINC01869 gene in a biological sample collected from the subject.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12N 15/09 - Recombinant DNA-technology
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

A method in which carbon dioxide can be efficiently fixed, calcium carbonate that is a valuable can be efficiently produced from carbon dioxide, and a waste gypsum board can be effectively recycled without being wasted as it is by using the waste gypsum board for fixing carbon dioxide. This method includes: bringing a first solution containing an alkali metal hydroxide and gas containing carbon dioxide into contact with each other to produce a second solution containing an alkali metal salt; and bringing the second solution and a gypsum-containing material into contact with each other to produce calcium carbonate.

IPC Classes  ?

• B01D 53/62 - Carbon oxides
• B01D 53/14 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by absorption
• B01D 53/78 - Liquid phase processes with gas-liquid contact
• C01F 11/18 - Carbonates

Abstract

A graft method according to the present invention comprises: a culture step in which a cell sheet is cultured on a culture surface of a culture carrier substrate; and a graft step in which the cell sheet formed on the culture surface of the culture carrier substrate is attached to a recipient site, after which the culture carrier substrate is detached from the cell sheet.

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 11/08 - Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer

Abstract

The present invention addresses the problem of providing a method for easily detecting hepatocellular carcinoma without depending only on AFP by using serum or the like collected in health diagnosis or the like.　In a body fluid collected from a subject, (A) the methylation level of CpG in DNA in a region of +1 to +1000 of a transcriptional regulatory region and/or a transcriptional initiation point of the SEPT9 gene or in a region of +1 to +1000 of a transcriptional regulatory region and/or a transcriptional initiation point of the HOXA1 gene and (B) the AFP level or the PIVKA-II level are measured by predetermined methods, statistical analysis is performed based on at least the two indices (A) and (B), and diagnosis of hepatocellular carcinoma in the subject is assisted on the basis of the value obtained by the statistical analysis.

IPC Classes  ?

• C12Q 1/6844 - Nucleic acid amplification reactions
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present invention addresses the problem of providing: a biomarker for stress level determination in order to determine the stress level of a subject by using a non-invasive and simple method; a detection method for the biomarker; a data collection method including the detection method; and a kit for the stress level determination.　This purpose can be achieved by using, as the biomarker, sialidase activity derived from bacteria in a sample acquired from a subject. The sample is preferably feces and/or the subject is preferably a human.

IPC Classes  ?

• C12Q 1/34 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor

Abstract

Provided is a calcium carbonate generation method and system in which calcium carbonate having a high purity can be generated using a calcium-containing waste. Provided is a calcium carbonate generation method of generating calcium carbonate from a calcium-containing waste, the calcium carbonate generation method including: a calcium dissolution step of adding aqueous hydrochloric acid to a calcium-containing waste and dissolving calcium to generate an aqueous solution containing a calcium ion; a separation step of adjusting a hydrogen ion concentration index of the aqueous solution containing a calcium ion and separating a component containing at least one selected from the group consisting of Si, Al, Mg, and heavy metal from the aqueous solution; and a calcium carbonate collection step of generating calcium carbonate using an aqueous solution obtained in the separation step and an aqueous solution containing potassium carbonate and/or sodium carbonate.

IPC Classes  ?

• C01F 11/18 - Carbonates
• B09B 3/70 - Chemical treatment, e.g. pH adjustment or oxidation
• B09B 101/45 - Concrete
• C01B 7/07 - Purification
• C01D 1/38 - PurificationSeparation by dialysis
• C01D 1/40 - PurificationSeparation by electrolysis
• C01D 7/07 - Preparation from the hydroxides

Abstract

The present invention addresses the problem of providing a cation exchange membrane having high selectivity for a specific cation, particularly an ammonium ion, and also having high energy efficiency in dialysis. The cation exchange membrane has a cation exchange layer containing a metal cyano complex and a binder resin.

IPC Classes  ?

• B01J 47/12 - Ion-exchange processes in generalApparatus therefor characterised by the use of ion-exchange material in the form of ribbons, filaments, fibres or sheets, e.g. membranes
• B01D 61/46 - Apparatus therefor
• B01J 39/19 - Macromolecular compounds obtained otherwise than by reactions only involving unsaturated carbon-to-carbon bonds

Abstract

The present invention addresses the problem of providing a method for simply measuring the methylation level of CpG in a transcription regulatory region of a gene to be measured, by performing a restriction enzyme treatment in which restriction enzymes are added only in one stage.　The solution is as follows.　Provided is a method for measuring the methylation level of CpG in a transcription regulatory region and/or a region from +1 nucleotide to +1000 nucleotides from a transcription initiation point in a gene to be measured, the method comprising steps (a) to (d): (a) a step for adding (i) DNA containing the gene to be measured, (ii) at least one restriction enzyme selected from HhaI, HpaII, etc., (iii) a restriction enzyme BstUI, and (iv) a restriction enzyme reaction buffer into a reaction vessel followed by sealing; (b) a step, while keeping the reaction vessel sealed, for performing a restriction enzyme treatment at a temperature of 30-50°C for 0.5-16 hours and then at 50-70°C for 0.5-20 hours; (c) a step for amplifying a part or the full length of a predetermined region in the gene to be measured; and (d) a step for measuring the methylation level of CpG in the DNA in the region having been amplified in step (c).

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/34 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12Q 1/686 - Polymerase chain reaction [PCR]

Abstract

The present disclosure addresses the problem of providing a cell population isolated from a living body and comprising mesenchymal cells that have a prescribed cell surface antigen molecule and can be used to produce a cell sheet.　The present invention uses a cell population isolated from a living body and comprising at least 80% mesenchymal cells that express at least one cell surface antigen molecule selected from the group consisting of CD13, CD59, CD49e, CD151, and CD280. It is preferable that the mesenchymal cells are cells collected from intraoral tissue or are a culture thereof, and that the mesenchymal cells express at least three cell surface antigen molecules selected from the group consisting of CD13, CD59, CD49e, CD151, and CD280.

IPC Classes  ?

• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• A61K 35/38 - StomachIntestineGoblet cellsOral mucosaSaliva
• A61L 27/38 - Animal cells
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The present disclosure provides a composition comprising a nucleic acid delivery vehicle, a nucleic acid encoding interleukin-7 (IL-7), and a nucleic acid encoding chemokine (C-C motif) ligand 19 (CCL19), and its use thereof.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61P 35/00 - Antineoplastic agents
• C07K 14/52 - CytokinesLymphokinesInterferons
• C07K 14/54 - Interleukins [IL]
• C07K 14/725 - T-cell receptors

Abstract

The present invention addresses the problem of providing an antibody that specifically binds to feline PD-1 and that has an activity to inhibit binding between feline PD-1 and feline PD-L1.　In the present invention, obtained is an antibody that includes a specific heavy-chain complementary determining regions (CDR) 1 to 3 and a specific light-chain CDR 1 to 3 and that specifically binds to feline PD-1.

IPC Classes  ?

• C12N 15/13 - Immunoglobulins
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

It is to provide an immunocompetent cell that expresses regulatory factors of immunocompetent cell immune function and possesses all of proliferative potential, viability, and the ability to accumulate a T cell, and an expression vector of regulatory factors of immune function for generating the immunocompetent cell. An immunocompetent cell expressing a cell surface molecule specifically recognizing a cancer antigen, interleukin 7 (IL-7), and CCL19 is generated. Preferably, the cell surface molecule specifically recognizing a cancer antigen is T cell receptor specifically recognizing the cancer antigen, and the immunocompetent cell is a T cell.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/54 - Interleukins [IL]
• C07K 14/725 - T-cell receptors
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/09 - Recombinant DNA-technology
• C12N 15/79 - Vectors or expression systems specially adapted for eukaryotic hosts

Abstract

The present invention addresses the problem of providing a catalyst that has a high catalytic activity and can be used as a catalyst for oxygen evolution reaction.　Provided is a catalyst for oxygen evolution reaction in which an iron tungstate is carried on the surface of a nickel porous body.

IPC Classes  ?

• B01J 23/888 - Tungsten
• B01J 37/10 - Heat treatment in the presence of water, e.g. steam
• C25B 1/04 - Hydrogen or oxygen by electrolysis of water
• C25B 3/26 - Reduction of carbon dioxide
• C25B 9/00 - Cells or assemblies of cellsConstructional parts of cellsAssemblies of constructional parts, e.g. electrode-diaphragm assembliesProcess-related cell features
• C25B 11/031 - Porous electrodes
• C25B 11/032 - Gas diffusion electrodes
• C25B 11/052 - Electrodes comprising one or more electrocatalytic coatings on a substrate
• C25B 11/054 - Electrodes comprising electrocatalysts supported on a carrier
• C25B 11/061 - Metal or alloy
• C25B 11/077 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of a single catalytic element or catalytic compound the compound being a non-noble metal oxide
• C25B 11/091 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of at least one catalytic element and at least one catalytic compoundElectrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of two or more catalytic elements or catalytic compounds

Abstract

The present invention simply estimates a disease condition of an asthmatic patient.　An asthmatic disease condition estimation server (1) according to the present invention comprises: a storage unit (2) which stores, in association with a plurality of disease conditions of asthma, a plurality of clusters into which asthmatic patients are classified; a receiving unit (3) which receives symptom information indicating the symptom of a patient to be determined; a determination unit (4) that, on the basis of the symptom information, specifies a cluster, to which the patient to be determined belongs, among the plurality of clusters, and that specifies a disease condition stored in the storage unit in association with the specified cluster; and an output unit (5) which outputs the specified disease condition as an estimated disease condition of the patient to be determined.

IPC Classes  ?

• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

This nest material is made of a pulp sheet, has a plurality of incisions formed in the outer rim, and has a plurality of strip-shaped portions formed between the plurality of incisions. The nest material may have an elongated shape, have a plurality of incisions formed on one side of the outer rim along the longitudinal direction, and have a plurality of strip-shaped portions formed between the plurality of incisions. The nest material may be formed by folding a pulp sheet and shaping the folded pulp sheet into an elongated shape in a folded and overlapped state, and may have a plurality of incisions formed at a portion of the outer rim at the folded side of the pulp sheet on one side of the outer rim along the longitudinal direction, and have a plurality of strip-shaped portions between the incisions.

IPC Classes  ?

• A01K 1/035 - Devices for use in keeping domestic animals, e.g. fittings in housings or dog beds

Abstract

The present invention addresses the problem of providing an inhibitor for retinochoroidal disorders, in particular, an inhibitor for retinochoroidal scar formation and retinochoroidal atrophy in an epiretinal, intraretinal or subretinal tissue. This problem can be solved by preparing an inhibitor for retinochoroidal disorders which comprises, as an active ingredient, (E)-4-(2-{3-[(1H-pyrazol-1-yl)methyl]-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-yl}vinyl)benzoic acid, an ester thereof or a salt of the same. The inhibitor for retinochoroidal disorders can inhibit collagen atrophy of retinal pigment epithelium cells, fibroblasts, glial cells and the like and thus inhibit retinochoroidal disorders.

IPC Classes  ?

• A61K 31/415 - 1,2-Diazoles
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/06 - OintmentsBases therefor
• A61K 9/08 - Solutions
• A61K 9/20 - Pills, lozenges or tablets
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Abstract

The present invention improves the learning motivation of a learner.　A learning assistance server according to the present invention connects, in a contest mode, to a first terminal operated by a first respondent and a second terminal operated by a second respondent. The learning assistance server comprises: a reception unit that receives, from the first terminal, a first response from the first respondent that has been input into a first input screen displayed on the first terminal; a transmission unit that transmits the result of a determination as to whether the first response is correct or incorrect to the first terminal and the second terminal; and a display control unit that controls the first input screen so as to be in an on state in which it is possible to input the first response and an off state in which it is not possible to input the first response and controls a second input screen so as to be in an on state in which it is possible to input a second response by the second respondent and an off state in which it is not possible to input the second response. When the first input screen is controlled so as to be in the on state, the second input screen is controlled so as to be in the off state and the first response input into the first input screen and the determination result as to whether the first response is correct are displayed on the second terminal.

IPC Classes  ?

• G09B 5/08 - Electrically-operated educational appliances providing for individual presentation of information to a plurality of student stations
• G06Q 50/20 - Education
• G09B 5/02 - Electrically-operated educational appliances with visual presentation of the material to be studied, e.g. using film strip
• G09B 19/00 - Teaching not covered by other main groups of this subclass
• G09B 19/06 - Foreign languages

Abstract

[Problem] To provide an agent which is safe even when ingested for a long period and can improve the intestinal microflora of a dog. [Solution] This agent for improving the intestinal flora of a dog contains nicotinamide mononucleotide as an active ingredient, wherein the improving of the intestinal flora of a dog reduces the proportion of bad bacteria in the intestinal flora of a dog.

IPC Classes  ?

• A23K 50/40 - Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
• A23K 20/121 - Heterocyclic compounds containing oxygen or sulfur as hetero atom
• A23K 20/132 - Heterocyclic compounds containing only one nitrogen as hetero atom
• A23L 33/13 - Nucleic acids or derivatives thereof
• A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
• A61P 1/12 - Antidiarrhoeals

Abstract

Provided are a sodium titanium phosphate salt and, additionally, at least one of a negative electrode active material that gives a sodium secondary battery having superior power characteristics as compared to conventional aqueous sodium secondary batteries and a sodium secondary battery including such a negative electrode active material. In particular, provided is a negative electrode active material that gives an aqueous sodium secondary battery having superior power characteristics as compared to conventional aqueous sodium secondary batteries including NASICON type NaTi2(PO4)3 as a negative electrode active material. Provided are a sodium titanium phosphate salt and, additionally, at least one of a negative electrode active material that gives a sodium secondary battery having superior power characteristics as compared to conventional aqueous sodium secondary batteries and a sodium secondary battery including such a negative electrode active material. In particular, provided is a negative electrode active material that gives an aqueous sodium secondary battery having superior power characteristics as compared to conventional aqueous sodium secondary batteries including NASICON type NaTi2(PO4)3 as a negative electrode active material. A sodium titanium phosphate salt represented by the general formula Na1+xTi2(PO4)3 (where 0≤x≤2) includes a surface layer containing Na5Ti(PO4)3.

IPC Classes  ?

• H01M 4/58 - Selection of substances as active materials, active masses, active liquids of inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFySelection of substances as active materials, active masses, active liquids of polyanionic structures, e.g. phosphates, silicates or borates
• C01B 25/45 - Phosphates containing plural metal, or metal and ammonium
• H01M 4/36 - Selection of substances as active materials, active masses, active liquids
• H01M 10/36 - Accumulators not provided for in groups

Abstract

The present invention addresses the problem of providing a method whereby environmental DNA or environmental RNA can be captured using a carrier having a high holding force, and the captured environmental DNA or environmental RNA can subsequently be efficiently recovered from the carrier.　The method performed for recovering environmental DNA or environmental RNA from an environmental sample includes steps (a) and (b), in order, where (a) is a step for bringing the environmental sample containing the environmental DNA or the environmental RNA into contact with a nucleic acid capturing carrier comprising a flexible porous material to capture the environmental DNA or the environmental RNA or a biological sample containing the environmental DNA or the environmental RNA on the nucleic acid capturing carrier, and (b) is a step for positively or negatively pressurizing the nucleic acid capturing carrier.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA

Abstract

A lithium ion secondary battery includes a negative electrode including a mixture layer which contains a niobium titanium oxide as a negative electrode active material, and non-aqueous electrolyte containing lithium alkoxysulfonate represented by RSOOO−Li+ (where R is at least one selected from the group consisting of OCH3 and OC2H5).

IPC Classes  ?

• H01M 10/0568 - Liquid materials characterised by the solutes
• H01M 4/36 - Selection of substances as active materials, active masses, active liquids
• H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
• H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
• H01M 10/0569 - Liquid materials characterised by the solvents

Abstract

Provided are: a bipolar membrane electrodialyzer which has a high electric-current efficiency and in which the cation-exchange membrane is inhibited from suffering scale deposition therein due to divalent cations; and a method for operating the bipolar membrane electrodialyzer.　The method is for operating a bipolar membrane electrodialyzer configured of a bipolar membrane, a cation-exchange membrane, and an anion-exchange membrane, the method comprising using the bipolar membrane electrodialyzer to yield an acid and an alkali from brine and being characterized by conducting electrodialysis while regulating the acid solution and/or the alkali solution so as to contain a salt to be decomposed.

IPC Classes  ?

• C02F 1/469 - Treatment of water, waste water, or sewage by electrochemical methods by electrochemical separation, e.g. by electro-osmosis, electrodialysis, electrophoresis
• B01D 61/44 - Ion-selective electrodialysis
• B01D 61/46 - Apparatus therefor

Abstract

Provided are a production method and a production system of calcium carbonate that utilize a calcium-containing waste and can control the alkali content in the obtained calcium carbonate.　The calcium carbonate production method for producing calcium carbonate from a calcium-containing waste includes: a calcium dissolution step for adding an aqueous hydrochloric acid solution to the calcium-containing waste and dissolving calcium to prepare an aqueous solution containing calcium ions; a separation step for adjusting the hydrogen ion concentration index of the aqueous solution containing calcium ions to separate Mg, etc. from the aqueous solution; and a calcium carbonate preparation step for adding an aqueous solution containing potassium carbonate and/or sodium carbonate to the aqueous solution containing calcium ions obtained in the separation step and reacting to prepare calcium carbonate. In this calcium carbonate production method (system), in the calcium carbonate preparation step, the rate of the addition of the aqueous solution containing potassium carbonate and/or sodium carbonate is controlled so as to adjust κ, which is represented by a specific formula, to 3000 or less.

IPC Classes  ?

• C01F 11/18 - Carbonates
• B09B 3/70 - Chemical treatment, e.g. pH adjustment or oxidation

Abstract

The present invention enables the achievement of a method for efficiently producing a reusable electrode active material by regenerating a used active material, which is contained in an electrode of a used secondary battery, by a simple process that has a reduced environmental impact. This method for producing an electrode active material produces a reusable electrode active material by regenerating a used active material which is contained in an electrode of a used secondary battery. With respect to this method for producing an electrode active material, the electrode is provided with a collector and an electrode mixture that is formed on the collector and contains an active material; and this method comprises a step (step S1) in which the electrode mixture is separated from the collector by immersing the electrode in an aqueous alkaline solution, and a step (step S2) in which the separated electrode mixture is neutralized.

IPC Classes  ?

• H01M 10/54 - Reclaiming serviceable parts of waste accumulators
• H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
• H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy

Abstract

In the present invention, an SF3B1 gene mutation associated with MDS prognosis prediction is detected at high accuracy. A blocking nucleic acid that contains a base sequence complementary to a non-target nucleic acid containing a plurality of bases not to be detected that correspond to bases to be detected at a plurality of mutation locations associated with MDS in the SF3B1 gene is used.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C12Q 1/6837 - Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
• C12Q 1/686 - Polymerase chain reaction [PCR]
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

The present invention has an object to provide a D-mannose isomerase of membrane-bound form having the optimal reaction pH in acidic region. The present invention has an object to provide a D-mannose isomerase of membrane-bound form having the optimal reaction pH in acidic region. The membrane-bound D-mannose isomerase derived from acetic acid bacteria is produced. The acetic acid bacteria are preferably belong to the genera of Acetobacter, Gluconobacter, or Gluconacetobacter. Furthermore, the membrane-bound D-mannose isomerase from the acetic acid bacteria is used to produce D-fructose from D-mannose.

IPC Classes  ?

• C12N 9/90 - Isomerases (5.)
• C12N 11/02 - Enzymes or microbial cells immobilised on or in an organic carrier
• C12P 19/02 - Monosaccharides

Abstract

An object of the present invention is to provide a method for amplifying a nucleic acid using a PCR reaction solution with a volume as large as 30 mL or more, and an apparatus for amplifying a nucleic acid using a PCR reaction solution with a volume as large as 30 mL or more. The present invention provides a method for amplifying a nucleic acid, comprising performing polymerase chain reaction (PCR) by controlling a temperature of one or more reaction container(s) housing a reaction solution containing a DNA polymerase, deoxyribonucleotide triphosphates (dNTPs), a template DNA, a forward primer, a reverse primer, and a buffer solution, wherein the reaction solution is in an amount of 30 mL or more, and the polymerase chain reaction is performed while the reaction solution is stirred.

IPC Classes  ?

• C12Q 1/6844 - Nucleic acid amplification reactions
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• B01L 7/00 - Heating or cooling apparatusHeat insulating devices

Abstract

An object of the present invention is to provide: an anti-GPC3 antibody that recognizes an epitope different from that for existing antibodies (e.g., GC33 and GC199) and can specifically bind, even in the form of single chain antibody, to GPC3 localized on a cell membrane; CAR comprising the anti-GPC3 single chain antibody; an immunocompetent cell expressing the CAR; a gene of the anti-GPC3 antibody or a gene of the CAR; a vector comprising the anti-GPC3 antibody gene or the CAR gene; a host cell in which the vector has been introduced; a method for specifically detecting GPC3; and a kit for specifically detecting GPC3. An antibody comprising particular heavy chain CDR1 to CDR3 and particular light chain CDR1 to CDR3 defined in claim 1, and specifically binding to a human-derived GPC3 polypeptide specifically binds to GPC3 localized on a cell membrane. CAR-immunocompetent cells prepared on the basis of CAR comprising such single chain antibody are useful for cancer immunotherapy.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C07K 14/54 - Interleukins [IL]
• C07K 14/725 - T-cell receptors
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C12N 5/078 - Cells from blood or from the immune system
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

2332222C≡N group.

IPC Classes  ?

• H01M 10/0567 - Liquid materials characterised by the additives
• H01M 4/48 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides
• H01M 10/052 - Li-accumulators

Abstract

The purpose of the present invention is: to provide a manual muscle strength testing device with which it is possible, by using an inertial sensor and a load exercise measurement device of simple configuration, to capture very small muscle contractions of the fingers while suppressing the compensatory effects of surrounding muscles; and to make it possible to evaluate the state or the degree of recovery of the median, ulnar, and radial nerves by measuring only a load exercise of the index finger.　A manual muscle strength testing device according to the present invention has, inter alia: a finger insertion part 30, comprising an other finger fixation part 28 having a space that is shaped so as to prevent movement, in any direction, of a middle, a ring, or little finger inserted thereinto, and an index finger insertion part 29 having a space that is shaped such that an inserted index finger is able to move towards the pad side or the thumb side, or the fingernail side or the thumb side; a ring 15 that can be fitted onto the fingertip of the index finger; a pressure sensor 32 capable of measuring the size of a load acting on the fingertip and a 3-axis acceleration sensor 11 capable of measuring the movement of the fingertip, fixed to the ring 15; and a load elastic body 31 that applies an adjustable load to the fingertip on which the ring 15 is worn.

IPC Classes  ?

• A61B 5/22 - ErgometryMeasuring muscular strength or the force of a muscular blow
• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb

Abstract

22/Mn2+22/Mn2+oxidation-reduction pair and higher than the standard electric potential of a Zn2+/Zn oxidation-reduction pair. Additionally, a secondary battery provided with a positive electrode, a negative electrode, and the above-mentioned aqueous electrolytic liquid, the active material of the negative electrode being zinc.

IPC Classes  ?

• H01M 10/36 - Accumulators not provided for in groups
• H01M 4/42 - Alloys based on zinc
• H01M 4/50 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese

Abstract

Disclosed are a UV irradiation device and a UV irradiation method with which it is possible to easily and adequately break down a biofilm.　The UV irradiation device comprises a light source unit having a light source for emitting UV light having a wavelength of 190-240 nm inclusive, and a support body for supporting the light source unit such that a biofilm is irradiated with the UV light emitted by the light source. The UV irradiation device irradiates the biofilm with UV light to break down the biofilm.

IPC Classes  ?

• A61L 2/10 - Ultraviolet radiation

Abstract

The present invention provides a pharmaceutical composition comprising cells expressing a chimeric receptor, for use in combination with administration of an antigen-binding molecule, wherein the chimeric receptor comprises an extracellular domain, the extracellular domain comprises an extracellular domain of an immunoreceptor, an extracellular domain variant of an immunoreceptor, or a portion thereof, and the antigen-binding molecule is a multispecific antigen-binding molecule having a target antigen recognition site and an immunoreceptor recognition site which recognizes the immunoreceptor.

IPC Classes  ?

• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C12N 15/86 - Viral vectors
• A61P 35/00 - Antineoplastic agents
• C07K 14/725 - T-cell receptors
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

A cell culture method and a cell culture device used with the cell culture method allow mass-producing a three-layer blood-brain barrier (BBB) in vitro model including a vascular endothelial cell, a pericyte, and an astrocyte. A cell culture method enhances mass production of the three-layer BBB models. A cell culture method includes injecting a suspended cell culture medium into an outer surface of a porous membrane in a cell culture insert, seeding the cell culture medium with an astrocyte to culture the astrocyte, seeding the cell culture insert being inverted with a pericyte to culture the pericyte, seeding the cell culture insert with a temperature-sensitive vascular endothelial cell embedded in a temperature-sensitive gel to culture the vascular endothelial cell, and melting the temperature-sensitive gel.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
• C12M 1/00 - Apparatus for enzymology or microbiology

Abstract

It is an object of the present invention to provide a reversible opening agent for the neural vascular barrier. It is an object of the present invention to provide a reversible opening agent for the neural vascular barrier. As a solution, the reversible opening agent for the neural vascular barrier is prepared by including a ligand having an agonistic effect on basigin as an active ingredient. It is preferable that the above ligand contains a polypeptide consisting of an amino acid sequence shown in SEQ ID NO: 1 or the like, or a salt thereof as the active ingredient or the above ligand is cyclophilin A lacking peptidyl-prolyl cis-trans isomerase activity.

IPC Classes  ?

• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

An elongated ferromagnetic anodic electrode is fixed to a tightly closable pipe shape vacuum casing so as to extend within the casing as a cantilever and magnetic field applying module is disposed so as to concentrate magnetic field at a tip side position of the ferromagnetic anodic electrode in an area of discharge optical emission when a high voltage is applied between the anodic electrode and the vacuum casing as a cathode electrode. In addition, a vacuum casing can be formed with a ferromagnetic and soft magnetic material for magnetic flux to be permeable well, or a tip side alone of an anodic electrode rather than the anodic electrode itself can be formed with a ferromagnetic material, or a ferromagnetic member can be disposed at a near position of an anodic electrode, so as to concentrate magnetic field in a vicinity of a tip of an anodic electrode.

IPC Classes  ?

• G01N 21/67 - Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light electrically excited, e.g. electroluminescence using electric arcs or discharges
• G01M 3/40 - Investigating fluid tightness of structures by using electric means, e.g. by observing electric discharges
• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups

Abstract

The present invention addresses the problem of providing a novel therapeutic agent for keratoconjunctive disorders. As a means for solving the problem, a therapeutic agent for keratoconjunctive disorders which contains a RARγ agonist as an active ingredient is provided. The therapeutic agent exhibits an excellent ameliorating effect in a keratoconjunctive disorder model, and is therefore useful as a therapeutic agent for keratoconjunctive disorders such as corneal ulcer, corneal epithelial abrasion, keratitis, dry eye, conjunctivitis, chronic superficial keratitis, corneal erosion, persistent corneal disorders, superficial punctate keratopathy, corneal epithelial defects, conjunctival epithelial defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis, filamentary keratoconjunctivitis, infectious keratitis, noninfectious keratitis, infectious conjunctivitis and noninfectious conjunctivitis. The therapeutic agent is also useful as a therapeutic agent for corneal scarring and conjunctival scarring both associated with keratoconjunctive disorders.

IPC Classes  ?

• A61K 31/415 - 1,2-Diazoles
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/06 - OintmentsBases therefor
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Abstract

For measuring the stress history in a simple form, which is widely applicable to various types of structural materials which the elastic modulus is different from each other, a large number of calcite particles is embedded as a stress sensor in a cement-based composite material that can be elastically deformed after receiving an external. For measuring the stress history in a simple form, which is widely applicable to various types of structural materials which the elastic modulus is different from each other, a large number of calcite particles is embedded as a stress sensor in a cement-based composite material that can be elastically deformed after receiving an external. A twin-crystal density of the calcite particles is measured after an external force is applied to the composite material, to convert the twin-crystal density to a strain by an approximate formula set in terms of a strain ε (%) generated in the composite material and a twin-crystal density Dtw (lines/mm) of the calcite particles, and further to convert this strain to a stress by the elastic modulus of the composite material, whereby to estimate the history of stress and strain. The approximate formula between strain and twin-crystal density is independent of the modulus of the composite material and is used in a common form.

IPC Classes  ?

• G01L 1/06 - Measuring force or stress, in general by measuring the permanent deformation of gauges, e.g. of compressed bodies
• G01N 33/38 - ConcreteLimeMortarGypsumBricksCeramicsGlass
• C04B 14/28 - Carbonates of calcium
• C04B 20/00 - Use of materials as fillers for mortars, concrete or artificial stone according to more than one of groups and characterised by shape or grain distributionTreatment of materials according to more than one of the groups specially adapted to enhance their filling properties in mortars, concrete or artificial stoneExpanding or defibrillating materials
• C04B 20/10 - Coating or impregnating

Abstract

The present invention provides a method whereby carbon dioxide can be efficiently fixed and calcium carbonate, which is a valuable, can be efficiently produced from the carbon dioxide, and whereby waste gypsum boards can be effectively utilized for fixing carbon dioxide without being discarded. This method comprises a first step, in which a first solution, which contains an alkali metal hydroxide, is brought into contact with a gas including carbon dioxide to thereby yield a second solution, which contains an alkali metal salt, and a second step, in which the second solution is brought into contact with a gypsum-containing substance to thereby yield calcium carbonate.

IPC Classes  ?

• C01F 11/18 - Carbonates
• B01D 53/62 - Carbon oxides
• B01D 53/75 - Multi-step processes
• B01D 53/78 - Liquid phase processes with gas-liquid contact

Abstract

Provided are a calcium carbonate generation method and a system that make it possible to use calcium-containing waste to generate high-purity calcium carbonate.　According to the present invention, a calcium carbonate generation method that generates calcium carbonate from calcium-containing waste is characterized by having a calcium dissolution step for adding aqueous hydrochloric acid to the calcium-containing waste to dissolve the calcium and generate an aqueous solution that includes calcium ions, a separation step for adjusting a hydrogen ion concentration index for the aqueous solution that includes the calcium ions and separating a component that includes at least one substance selected from the group that consists of Si, Al, Mg, and heavy metals from the aqueous solution, and a calcium carbonate recovery step for using the aqueous solution obtained via the separation step and an aqueous solution that includes potassium carbonate and/or sodium carbonate to generate calcium carbonate.

IPC Classes  ?

• C01F 11/18 - Carbonates
• B09B 3/70 - Chemical treatment, e.g. pH adjustment or oxidation
• C01D 7/32 - Purification by dialysis
• C04B 7/60 - Methods for eliminating alkali metals or compounds thereof

Abstract

The cell vibration microdevice has thirty-three microdevices 11 disposed on a glass substrate 12. Each microdevice 11 comprises: two fixed parts 13 that are fixed in the left and right directions on the glass substrate 12; a mobile microstage 14 capable of moving on the glass substrate 12; and two silicone beams 15 that connect the mobile microstage 14 with the left and right fixed parts 13. The mobile microstage 14 comprises: a cell attachment part 17 that enables the attachment and culture of cells on an upper surface; a frame part 18 that encloses the cell attachment part 17; and a probe contact part 19.　This cell vibration microdevice enables observation to be performed with the independent application of a desired acceleration or vibrational stimulation to a plurality of cells being cultured in one dish, and can also stabilize the direction of movement of a cell-seeding microchamber when the desired acceleration or vibrational stimulation is applied.

IPC Classes  ?

• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus

Abstract

The purpose of the present invention is to accurately evaluate the success or failure of an amplification reaction even in the presence of a blocking nucleic acid.　In the present invention, a reaction solution is brought into contact with a microarray equipped with common probes, and the success or failure of an amplification reaction is evaluated on the basis of the signal intensity from the common probes. MYD88 gene mutation can also be evaluated accurately according to the microarray kit.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
• C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism

Abstract

A lithium ion secondary battery which is provided with: a negative electrode that contains, as a negative electrode active material, niobium titanium oxide in a mixture layer; and a nonaqueous electrolyte solution that contains lithium alkoxy sulfonate represented by RSOOO-Li+3255). This lithium ion secondary battery achieves a good balance between output characteristics and energy density.

IPC Classes  ?

• H01M 4/48 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides
• H01M 4/485 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of mixed oxides or hydroxides for inserting or intercalating light metals, e.g. LiTi2O4 or LiTi2OxFy
• H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
• H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
• H01M 10/0567 - Liquid materials characterised by the additives
• H01M 10/0568 - Liquid materials characterised by the solutes
• H01M 10/0569 - Liquid materials characterised by the solvents

Abstract

The present invention addresses the problem of providing an ion exchange membrane with which: the surface area of a membrane effective for ion permeation can be increased; an electrical resistance of a flow passage between membranes and attachment of contaminating substances are appropriately reduced; the mechanical strength of the membrane itself is increased; and there is little deformation or damage due to swelling over a wide range of salt concentrations even if there is a large difference in the salt concentrations between two solutions that are in contact with the membrane.　This ion exchange membrane, which has an undulating shape, has a flat portion in the vicinity of an end, protruding curved portions and recessed curved portions resulting from curvature of the ion exchange membrane itself respectively form projecting portions and recessed portions in the undulating shape of the ion exchange membrane, the projecting portions extend with a linear shape or a curved shape, the recessed portions between the projecting portions are flat, the recessed portions include first recessed portions that extend in a longitudinal direction of the projecting portions and that are adjacent to one another in a lateral direction of the projecting portions, the projecting portions have an apex portion and side surfaces in the longitudinal direction, and the side surfaces are inclined from the apex portion toward the first recessed portions.

IPC Classes  ?

• B01D 61/46 - Apparatus therefor
• C08J 5/22 - Films, membranes or diaphragms
• B01J 39/04 - Processes using organic exchangers
• B01J 39/05 - Processes using organic exchangers in the strongly acidic form
• B01J 39/19 - Macromolecular compounds obtained otherwise than by reactions only involving unsaturated carbon-to-carbon bonds
• B01J 39/20 - Macromolecular compounds obtained by reactions only involving unsaturated carbon-to-carbon bonds
• B01J 41/04 - Processes using organic exchangers
• B01J 41/05 - Processes using organic exchangers in the strongly basic form
• B01J 41/13 - Macromolecular compounds obtained otherwise than by reactions only involving unsaturated carbon-to-carbon bonds
• B01J 41/14 - Macromolecular compounds obtained by reactions only involving unsaturated carbon-to-carbon bonds
• B01J 47/12 - Ion-exchange processes in generalApparatus therefor characterised by the use of ion-exchange material in the form of ribbons, filaments, fibres or sheets, e.g. membranes
• C25B 13/02 - DiaphragmsSpacing elements characterised by shape or form
• C25B 13/08 - DiaphragmsSpacing elements characterised by the material based on organic materials

Abstract

The present disclosure provides a pharmaceutical composition comprising an antibody having ADCC activity, a T cell-redirecting antibody, or a cell expressing a chimeric receptor, for use in combination with the administration of an antigen binding molecule capable of binding to a target antigen, wherein the primary molecule comprises a linker that is cleaved by protease, the antigen binding molecule obtained through the cleavage of the linker has the ability to bind to the target antigen, variable regions of the antibody having ADCC activity or the T cell-redirecting antibody, and an extracellular binding domain of the chimeric receptor bind to a cell expressing the target antigen via binding to the antigen binding molecule resulting from the cleavage of the cleavable linker.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes

Abstract

The present invention addresses the problem of providing a suppressant for nervous system vascular barrier breakdown. Provided is a suppressant for nervous system vascular barrier breakdown, the suppressant comprising (a) or (b) as an active ingredient: (a) an enzyme capable of specifically detaching or decomposing a sugar chain of low-glycosylated basigin; and (b) an antibody, an aptamer, or a lectin that specifically binds to low-glycosylated basigin and suppresses the nervous system vascular barrier breakdown caused by basigin.　Preferably, the sugar chain of the low-glycosylated basigin is high-mannose sugar chain.

IPC Classes  ?

• A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
• A61K 38/02 - Peptides of undefined number of amino acidsDerivatives thereof
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 9/14 - VasoprotectivesAntihaemorrhoidalsDrugs for varicose therapyCapillary stabilisers
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 27/02 - Ophthalmic agents

Abstract

The present invention addresses the problem of providing a catalyst having high catalytic activity such as an oxygen reduction reaction and a hydrogen generation reaction, and particularly, providing a catalyst using platinum group particles having a small particle diameter. This layered manganese oxide contains platinum group metal particles between layers. Provided is a method for preparing platinum group metal particles or a layered manganese oxide containing platinum group metal particles between layers, the method comprising introducing a platinum group complex between layers of the layered manganese oxide and reducing the introduced platinum group complex by electrolysis, wherein the potential applied to the platinum group complex is changed in the positive direction and the negative direction.

IPC Classes  ?

• C25B 1/21 - Manganese oxides
• B01J 23/656 - Manganese, technetium or rhenium
• B01J 37/16 - Reducing
• C01G 45/02 - Oxides
• C25B 11/093 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of at least one catalytic element and at least one catalytic compoundElectrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of two or more catalytic elements or catalytic compounds at least one noble metal or noble metal oxide and at least one non-noble metal oxide
• C25B 15/02 - Process control or regulation
• C25C 5/02 - Electrolytic production, recovery or refining of metal powders or porous metal masses from solutions
• H01M 4/86 - Inert electrodes with catalytic activity, e.g. for fuel cells
• H01M 4/88 - Processes of manufacture
• H01M 4/92 - Metals of platinum group

Abstract

2435431+x2433 (wherein 0 ≤ x ≤ 2).

IPC Classes  ?

• C01B 25/45 - Phosphates containing plural metal, or metal and ammonium
• H01M 4/36 - Selection of substances as active materials, active masses, active liquids
• H01M 4/58 - Selection of substances as active materials, active masses, active liquids of inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFySelection of substances as active materials, active masses, active liquids of polyanionic structures, e.g. phosphates, silicates or borates
• H01M 10/054 - Accumulators with insertion or intercalation of metals other than lithium, e.g. with magnesium or aluminium
• H01M 10/36 - Accumulators not provided for in groups

Abstract

It is to provide an immunocompetent cell that expresses regulatory factors of immunocompetent cell immune function and possesses all of proliferative potential, viability, and the ability to accumulate a T cell, and an expression vector of regulatory factors of immune function for generating the immunocompetent cell. An immunocompetent cell expressing a cell surface molecule specifically recognizing a cancer antigen, interleukin 7 (IL-7), and CCL19 is generated. Preferably, the cell surface molecule specifically recognizing a cancer antigen is T cell receptor specifically recognizing the cancer antigen, and the immunocompetent cell is a T cell.

IPC Classes  ?

• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/54 - Interleukins [IL]
• C07K 14/725 - T-cell receptors
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 15/09 - Recombinant DNA-technology
• C12N 15/79 - Vectors or expression systems specially adapted for eukaryotic hosts

Abstract

A problem addressed by the present invention is to provide a membrane-bound D-mannose isomerase having an optimum reaction pH in the acidic region.　Membrane-bound D-mannose isomerase derived from acetic acid bacteria is produced. The acetic acid bacteria preferably belong to the genus Acetobacter, Gluconobacter, or Gluconacetobacter. Also, fructose is produced from D-mannose using the membrane-bound D-mannose isomerase derived from acetic acid bacteria.

IPC Classes  ?

• C12N 9/90 - Isomerases (5.)
• C12N 11/02 - Enzymes or microbial cells immobilised on or in an organic carrier
• C12P 19/02 - Monosaccharides

Abstract

The present invention accurately detects methylation of the MLH1 gene and a spontaneous mutation (V600E) in the BRAF gene. A step for treating sample genome DNA with bisulfite, wherein a region for detecting methylation of the MLH1 gene and a region which includes the V600E spontaneous mutation site in the BRAF gene are each amplified by using a pair of primers, and the region for detecting methylation of the MLH1 gene and the region which includes the V600E spontaneous mutation site in the BRAF gene which are contained in the amplicon are detected by using a probe.

IPC Classes  ?

• C12Q 1/6813 - Hybridisation assays
• C12N 15/09 - Recombinant DNA-technology
• C12Q 1/6844 - Nucleic acid amplification reactions
• C12Q 1/6874 - Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation [SBH]
• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention addresses the problem of providing: a method for amplifying nucleic acids using at least 30 mL of a large-capacity PCR reaction solution; and a device that amplifies nucleic acids using at least 30 mL of a large-capacity PCR reaction solution.　The problem is solved by a nucleic acid amplification method in which a polymerase chain reaction is performed by controlling the temperature of one or more reaction vessels accommodating a reaction solution that contains DNA polymerase, deoxyribonucleotide triphosphate (dNTP), a template DNA, a forward primer, a reverse primer, and a buffer solution, wherein the reaction solution is at least 30 mL, and the reaction solution is stirred while the polymerase chain reaction is carried out.

IPC Classes  ?

• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
• C12N 15/12 - Genes encoding animal proteins
• C12N 15/31 - Genes encoding microbial proteins, e.g. enterotoxins
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C12Q 1/686 - Polymerase chain reaction [PCR]

Abstract

The present disclosure provides a pharmaceutical composition for use in combination with administration of a mutated antibody having a mutation, including substitution, deletion, addition or modification, of at least one amino acid in a CH1 region, a CH2 region, a CH3 region, a CL region, or a framework region, wherein the pharmaceutical composition comprises a cell expressing a chimeric receptor, the mutated antibody is capable of binding to the extracellular binding domain of the chimeric receptor via a moiety having the mutation, and the extracellular binding domain does not bind to an antibody free of the mutation.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

The present invention provides: a cell culture method that enables mass production of a BBB model which has a three-layer structure comprising vascular endothelial cells, pericytes, and astrocytes; a cell culture device that is used for the cell culture method; and a cell culture method that enables an increase in mass productivity of the BBB model.　A cell culture method according to the present invention comprises: a step for dispensing a culture solution that is in a suspension state onto the outer surface of a porous film of a cell culture insert; a step for seeding astrocyte cells in the culture solution and culturing astrocytes; a step for seeding pericyte cells inside the cell culture insert that has been turned upside down, and culturing pericytes; a step for seeding thermosensitive vascular endothelial cells that are embedded in thermosensitive gel, and culturing vascular endothelial cells; and a step for dissolving the thermosensitive gel.

IPC Classes  ?

• C12M 1/00 - Apparatus for enzymology or microbiology
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/079 - Neural cells

Abstract

x1-x4x1-x44 (that is, 0

IPC Classes  ?

• C01G 53/00 - Compounds of nickel
• B01J 23/30 - Tungsten
• B01J 37/08 - Heat treatment
• B01J 37/10 - Heat treatment in the presence of water, e.g. steam
• C01B 13/08 - Preparation of oxygen from air with the aid of metal oxides, e.g. barium oxide, manganese oxide
• C25B 11/073 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material

Abstract

A novel agent is for treating or preventing a glioma. A marker for malignancy of a brain tumor and a prognostic marker for a brain tumor can be used in a method for determining malignancy of a brain tumor and a method for determining a prognosis for a brain tumor patient. The agent for treating or preventing a glioma can include an HVEM inhibitor as an active ingredient. The marker for malignancy of a brain tumor and the prognostic marker for a brain tumor can each include an HVEM protein or an HVEM gene. The method for determining malignancy of a brain tumor and the method for determining a prognosis for a brain tumor patient can each include measuring an HVEM expression amount in a biological sample of a subject.

IPC Classes  ?

• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61P 35/00 - Antineoplastic agents
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans

Abstract

The present invention addresses the problem of providing a composition for fluid tracing that contains a tracer having few adverse effects upon the environment, and having improved stability and recovery efficiency.　Provided as a solution is a composition for fluid tracing that is characterized by containing a tracer comprising as constituent components nucleic acid molecules and holders holding the nucleic acid molecules, and a fluid tracing method using the composition.

IPC Classes  ?

• C12Q 1/6851 - Quantitative amplification
• C12Q 1/686 - Polymerase chain reaction [PCR]

Abstract

The present invention addresses the problem of providing a reversible opening agent for a nervous system vascular barrier.　To solve the problem, a reversible opening agent for a nervous system vascular barrier is prepared, the reversible opening agent comprising, as an active ingredient, a ligand having an agonistic action on basigin. It is preferable that: the ligand contains, as an active ingredient, a polypeptide, etc., comprising an amino acid sequence represented in SEQ ID NO: 1 or a salt thereof; and the ligand is a cyclophilin A that has lost peptidyl-prolyl cis-trans isomerase activity thereof.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/08 - AntiepilepticsAnticonvulsants
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 27/02 - Ophthalmic agents
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof

Abstract

Through the present invention, there is provided a pharmaceutical composition that includes cells expressing a chimeric receptor, for use in combination with administration of an antigen-binding molecule, the chimeric receptor including an extracellular domain, the extracellular domain including an immunoreceptor extracellular domain, an immunoreceptor extracellular domain variant, or a fragment thereof, and the antigen-binding molecule being a multispecific antigen-binding molecule having a target antigen recognition site and an immunoreceptor recognition site that recognizes the immunoreceptor.

IPC Classes  ?

• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 19/00 - Hybrid peptides
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/12 - Genes encoding animal proteins
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

In order to measure the stress-strain history in a simple form that can be widely applied to various structural materials having different elastic moduli, a cement-based composite material in which a large number of calcite grains are embedded as stress sensors and can be elastically deformed by external force is subjected to external force and then the twin density in the calcite grains is measured, the twin density is converted to a strain using an approximation expression set for the strain ε (%) generated in the composite material and the twin density Dtw (counts/mm) in the calcite grains, and the strain is converted to a stress using the elastic modulus of the composite material to thereby estimate the stress-strain history generated in the composite material. A common approximation expression of strain-twin density is used regardless of the elastic modulus of the composite material.

IPC Classes  ?

• G01L 1/00 - Measuring force or stress, in general
• C04B 14/28 - Carbonates of calcium
• C04B 28/02 - Compositions of mortars, concrete or artificial stone, containing inorganic binders or the reaction product of an inorganic and an organic binder, e.g. polycarboxylate cements containing hydraulic cements other than calcium sulfates
• G01N 33/38 - ConcreteLimeMortarGypsumBricksCeramicsGlass

Abstract

The present invention addresses the problem of providing novel fluoroalkane derivatives that are of a low-molecular-weight type having no hydrogen-bonding functional groups in the molecule, are capable of gelling a wide range of organic solvents in a low concentration, and can form gelling agents that obtain a gel of adequate thermal stability and strength.　Fluoroalkane derivatives represented by formula (1) are used as gelling agents.　In formula (1), R1represents an alkyl group in which 60% or more of the hydrogen atoms have been substituted by fluorine atoms or a C1-30 hydrocarbon group having an alkyl group in which 60% or more of the hydrogen atoms have been substituted by fluorine atoms, Ar1represents a substituted or unsubstituted C3-20 divalent aromatic group, R represents a substituted or unsubstituted C1-30 hydrocarbon group or a group represented by formula (2) (in formula (2), Y1represents a cyano group, a nitro group, a substituted or unsubstituted C1-20 alkyl group, a substituted or unsubstituted C1-20 alkoxy group, a substituted or unsubstituted C1-20 alkylsulfanyl group, a substituted or unsubstituted C1-20 alkylsulfinyl group, or a substituted or unsubstituted C1-20 alkylsulfonyl group, Ar2 represents a substituted or unsubstituted C3-20 divalent aromatic group, and L represents a divalent linking group.), and n represents 1 or 2.

IPC Classes  ?

• C07C 317/14 - SulfonesSulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
• C07C 317/44 - SulfonesSulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
• C09K 3/00 - Materials not provided for elsewhere

Abstract

1+x2433 (wherein 0 ≤ x ≤ 2).

IPC Classes  ?

• C01B 25/37 - Phosphates of heavy metals
• H01M 4/36 - Selection of substances as active materials, active masses, active liquids
• H01M 4/58 - Selection of substances as active materials, active masses, active liquids of inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFySelection of substances as active materials, active masses, active liquids of polyanionic structures, e.g. phosphates, silicates or borates
• H01M 10/054 - Accumulators with insertion or intercalation of metals other than lithium, e.g. with magnesium or aluminium
• H01M 10/36 - Accumulators not provided for in groups

Abstract

An object of the present invention is to provide CAR-expressing T cells that coexpress a chimeric antigen receptor (CAR) and a T cell immune function-enhancing factor and have a high immunity-inducing effect and antitumor activity, and to provide a CAR expression vector for the preparation of the CAR-expressing T cells. An object of the present invention is to provide CAR-expressing T cells that coexpress a chimeric antigen receptor (CAR) and a T cell immune function-enhancing factor and have a high immunity-inducing effect and antitumor activity, and to provide a CAR expression vector for the preparation of the CAR-expressing T cells. A CAR expression vector comprises a nucleic acid encoding a chimeric antigen receptor (CAR) and a nucleic acid encoding a T cell immune function-enhancing factor, wherein the nucleic acid encoding an immune function-enhancing factor is a nucleic acid encoding interleukin-7 and a nucleic acid encoding CCL19, a nucleic acid encoding a dominant negative mutant of SHP-1, or a nucleic acid encoding a dominant negative mutant of SHP-2, or a CAR-expressing T cell introduced with the CAR expression vector are prepared.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 35/26 - LymphLymph nodesThymusSpleenSplenocytesThymocytes
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
• C12N 15/09 - Recombinant DNA-technology
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• C07K 14/52 - CytokinesLymphokinesInterferons
• C07K 14/54 - Interleukins [IL]
• C07K 14/725 - T-cell receptors
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

The present invention addresses the problem of providing: a polypeptide that contributes to polarization into M2 macrophages independent of IL-4; and an induction agent for differentiation or polarization into M2 macrophages.　A polypeptide derived from the human interleukin-4 receptor, the polypeptide being the result of modifying the amino acid sequence given by SEQ ID NO:1 by adding, deleting, or substituting one or more amino acids, preferably by substituting the 242nd isoleucine of the amino acid sequence given by SEQ ID NO:1 with asparagine.

IPC Classes  ?

• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/24 - Interleukins

Abstract

An information processor can logically support prediction based on past statistical information even though the information contains qualitative or non-numerical data. The processor determines whether an input pattern corresponding to an input object (a determination target) belongs to a specific class among multiple classes, based on feature subsets of any combination of a plurality of features, each feature comprises multiple categories. The processor includes a storage storing the input pattern corresponding to the input object and samples corresponding to respective sample objects and a classification determiner determining whether the input pattern belongs to the specific class. The classification determiner calculates a first conditional probability and a second conditional probability based on the number of the samples belonging to each category of the respective features, the first conditional probability is a probability that the data of the input pattern belong to categories corresponding to the respective feature for the specific class, the second conditional probability is a probability that the data of the input pattern belong to categories corresponding to the respective features for a non-specific class which is a class other than the specific class among classes, and the number of the samples is counted for each class based on the feature information on the samples and the class label information on the samples, and determines whether the input pattern belongs to the specific class based on the feature information on the input pattern, the first conditional probability and the second conditional probability.

IPC Classes  ?

• G06K 9/62 - Methods or arrangements for recognition using electronic means
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

It is intended to conveniently determine the pharmacokinetics of axitinib and to predict the therapeutic effect of axitinib. The present invention provides a method for determining the pharmacokinetics of axitinib, comprising the step of calculating a predicted pharmacokinetic parameter of axitinib using specific gene polymorphisms and background factors regarding a test subject.

IPC Classes  ?

• G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G16C 20/30 - Prediction of properties of chemical compounds, compositions or mixtures

Abstract

The present invention addresses the problem of providing an ion exchange membrane through which ions permeate easier than through a conventional profile membrane, which has a small pressure loss in a flow path, and in which clogging due to dirt can be reduced.　An ion exchange membrane having a concavo-convex shape has a flat portion near the end, and the curved protrusions and curved depressions created by the bending of the ion exchange membrane itself are the convex and concave portions in the concavo-convex shape of the ion exchange membrane, respectively.

IPC Classes  ?

• B01D 61/46 - Apparatus therefor
• B01D 61/50 - Stacks of the plate-and-frame type
• B01D 69/00 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or propertiesManufacturing processes specially adapted therefor
• B01D 69/12 - Composite membranesUltra-thin membranes
• C25B 13/02 - DiaphragmsSpacing elements characterised by shape or form
• C08J 5/22 - Films, membranes or diaphragms
• B01J 39/04 - Processes using organic exchangers
• B01J 39/19 - Macromolecular compounds obtained otherwise than by reactions only involving unsaturated carbon-to-carbon bonds
• B01J 41/04 - Processes using organic exchangers
• B01J 41/13 - Macromolecular compounds obtained otherwise than by reactions only involving unsaturated carbon-to-carbon bonds
• B01J 47/12 - Ion-exchange processes in generalApparatus therefor characterised by the use of ion-exchange material in the form of ribbons, filaments, fibres or sheets, e.g. membranes
• C02F 1/469 - Treatment of water, waste water, or sewage by electrochemical methods by electrochemical separation, e.g. by electro-osmosis, electrodialysis, electrophoresis

Abstract

The present invention addresses the problem of providing an inhibitor for retinochoroidal disorders, in particular, an inhibitor for retinochoroidal scar formation and retinochoroidal atrophy in an epiretinal, intraretinal or subretinal tissue. This problem can be solved by preparing an inhibitor for retinochoroidal disorders which comprises, as an active ingredient, (E)-4-(2-{3-[(1H-pyrazol-1-yl)methyl]-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-yl}vinyl)benzoic acid, an ester thereof or a salt of the same. The inhibitor for retinochoroidal disorders can inhibit collagen atrophy of retinal pigment epithelium cells, fibroblasts, glial cells and the like and thus inhibit retinochoroidal disorders.

IPC Classes  ?

• A61K 31/415 - 1,2-Diazoles
• A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions
• A61K 9/06 - OintmentsBases therefor
• A61K 9/20 - Pills, lozenges or tablets
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Abstract

The present invention addresses the problem of providing a novel medicine that is effective for preventing or treating angiogenesis-related diseases.　As a means for solving the problem, produced is a medicinal composition that comprises, as an active ingredient, 1-(cyclobutylcarbonyl)-3-(4-chlorophenyl)urea or a pharmacologically acceptable salt thereof. Preferably, the medicinal composition is used for preventing or treating angiogenesis-related diseases. Preferably, the angiogenesis-related diseases are ophthalmic angiogenesis-related diseases. Preferably, the ophthalmic angiogenesis-related diseases concern to the formation or constriction of fibrous scars in epiretinal, intraretinal and/or subretinal tissues.

IPC Classes  ?

• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 27/02 - Ophthalmic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine

Abstract

A method for culturing bone marrow-derived mesenchymal stem cells which is capable of efficiently culturing the cells while minimizing the influence of animal-derived serum by use of a serum-free medium. The method includes inoculating cells extracted from a bone marrow fluid to a culture vessel, and performing medium replacement a plurality of times before initial passage, wherein in the inoculation, a medium supplemented with animal-derived serum is used, and in any of the plurality of times of medium replacement, the medium is exchanged with a serum-free medium without the use of the serum, followed by culture in the serum-free medium.

IPC Classes  ?

• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor

Abstract

The present disclosure provides a pharmaceutical composition that is to be used in combination with administration of an antigen-binding molecule capable of binding to a target antigen, and that contains a cell which expresses an antibody having ADCC activity, a T cell-redirecting antibody, or a chimera receptor. The antigen-binding molecule as a primary molecule contains a linker which is to be cleaved by a protease. The antigen-binding molecule in which the linker is cleaved has the ability to bind to the target antigen. A variable domain of the antibody having ADCC activity or the T cell-redirecting antibody, and an extracellular binding domain of the chimera receptor, bind to a cell that expresses the target antigen, through binding to the antigen-binding molecule, in which the linker is cleaved, obtained after cleavage of the cleaved linker.

IPC Classes  ?

• A61K 35/14 - BloodArtificial blood
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia
• C07K 14/78 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C07K 19/00 - Hybrid peptides

Abstract

An object of the present invention is to provide an enhancer for endogenous T-cells or B-cells having a memory function and a malignant tumor recurrence inhibitor in order to continue to reject malignant tumor over a long period of time. An enhancer for T-cells or B-cells having a memory function in an administration subject, comprising a nucleic acid delivery vehicle, a nucleic acid encoding interleukin-7 (IL-7), and a nucleic acid encoding chemokine (C-C motif) ligand 19 (CCL19), and an inducer for inducing a memory function in T-cells or B-cells in an administration subject, are prepared. Also, a malignant tumor recurrence inhibitor comprising a nucleic acid delivery vehicle, a nucleic acid encoding interleukin-7 (IL-7), and a nucleic acid encoding CCL19, is prepared.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention addresses the problem of providing a novel therapeutic agent for keratoconjunctive disorders. As a means for solving the problem, a therapeutic agent for keratoconjunctive disorders which contains a RARγ agonist as an active ingredient is provided. The therapeutic agent exhibits an excellent ameliorating effect in a keratoconjunctive disorder model, and is therefore useful as a therapeutic agent for keratoconjunctive disorders such as corneal ulcer, corneal epithelial abrasion, keratitis, dry eye, conjunctivitis, chronic superficial keratitis, corneal erosion, persistent corneal disorders, superficial punctate keratopathy, corneal epithelial defects, conjunctival epithelial defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis, filamentary keratoconjunctivitis, infectious keratitis, noninfectious keratitis, infectious conjunctivitis and noninfectious conjunctivitis. The therapeutic agent is also useful as a therapeutic agent for corneal scarring and conjunctival scarring both associated with keratoconjunctive disorders.

IPC Classes  ?

• A61K 31/415 - 1,2-Diazoles
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/06 - OintmentsBases therefor
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Abstract

The present disclosure provides a pharmaceutical composition to be used in combination with the administration of a mutant antibody that has a mutation involving the substitution, deletion, addition or modification of at least one amino acid in the CH1 region, CH2 region, CH3 region, CL region or framework region thereof, wherein: the pharmaceutical composition comprises cells expressing a chimeric receptor; the mutant antibody is capable of binding to the extracellular binding domain of the chimeric receptor via a part containing the mutation in the extracellular binding domain; and the extracellular binding domain does not bind to an antibody not containing the mutation.　

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 15/13 - Immunoglobulins
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes

Abstract

10 aliphatic hydrocarbon group. Formulae (i) and (ii) are expressed as follows:

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient
• C07C 233/65 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
• A61K 8/42 - Amides
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids

Abstract

The purpose of the present invention is to provide a novel therapeutic or prophylactic agent for a glioma, a brain tumor malignancy marker, a brain tumor prognostic marker, a method for determining the malignancy of a brain tumor, and a method for determining the prognosis of a brain tumor patient. According to the present invention, provided are: a therapeutic and prophylactic agent for a glioma, said agent containing an HVEM inhibitor as an active ingredient; a brain tumor malignancy marker and a brain tumor prognostic marker, each marker comprising an HVEM protein or an HVEM gene; and a method for determining the malignancy of a brain tumor and a method for determining the prognosis of a brain tumor patient, each method comprising a step for measuring the HVEM expression level in a biological sample collected from a subject.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans

Abstract

The present invention easily identifies a genotype for gene mutations related to myeloproliferative neoplasms. The present invention comprises a mutant probe that specifically hybridizes with a gene mutation related to myeloproliferative neoplasms in JAK2, a mutant probe that specifically hybridizes with a gene mutation related to myeloproliferative neoplasms in CALR, and a mutant probe that specifically hybridizes with a gene mutation related to myeloproliferative neoplasms in MPL.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

An object of the present invention is to provide a simple and efficient device for predicting a risk of occurrence of a side effect of irinotecan by analyzing a single nucleotide polymorphism in a region encoding a specific gene. The prediction of the risk of the occurrence of a side effect of irinotecan is assisted by analyzing a single nucleotide polymorphism in a region encoding the APCDD1L gene, the R3HCC1 gene, the OR51I2 gene, the MKKS gene, the EDEM3 gene, or the ACOX1 gene which are present on genomic DNA in a biological sample collected from a test subject; or a single nucleotide polymorphism which is in linkage disequilibrium with or genetically linked to the single nucleotide polymorphism, and determining whether the single nucleotide polymorphism is homozygous for a variant type, heterozygous, or homozygous for a wild-type.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

A therapeutic effect of irinotecan is predicted using a predetermined genetic polymorphism. A genetic polymorphism identified by rs1980576 in APCDD1L gene, or a genetic polymorphism in linkage disequilibrium with the above genetic polymorphism is analyzed, and determination is performed based on the genotype of the genetic polymorphism.

IPC Classes  ?

• C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes

Abstract

A cylindrical indwelling medical device is formed by connecting a plurality of struts in a circumferential direction of the device in such a way to share a rib in an axial direction in neighboring struts to form annular or spiral columns of struts and connecting the columns of struts in the axial direction via links. Each strut has at least one set of strut pieces providing a bistable structure for supporting a load from reducing a diameter of the indwelling medical device and portions for inducing snap-through buckling deformation. load is in a direction preventing reverse snap-through buckling deformation to hold an expanded diameter state of the device. After the indwelling medical device with its diameter reduced has been introduced into a luminal organ and has expanded its diameter to indwell there, the device can resist sufficiently against the reduction in diameter, thus maintaining the expanded diameter state of the device.

IPC Classes  ?

• A61F 2/915 - Stents in a form characterised by wire-like elementsStents in a form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other

Abstract

It is an object to provide effective means for preventing and/or treating fulminant acute pneumonia. Provided are a pharmaceutical agent or pharmaceutical composition to be used for preventing and/or treating fulminant acute pneumonia, containing a CD69 antagonist, such as an antibody that specifically recognizes CD69 (anti-CD69 antibody), an agent for suppressing intra-alveolar neutrophil aggregation, containing a CD69 antagonist, such as an antibody that specifically recognizes CD69 (anti-CD69 antibody), an agent for suppressing pulmonary neutrophil infiltration, containing a CD69 antagonist, such as an antibody that specifically recognizes CD69 (anti-CD69 antibody), and a method of preventing and/or treating fulminant acute pneumonia, including administering a CD69 antagonist, such as an antibody that specifically recognizes CD69 (anti-CD69 antibody).

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

3s, and n m's each may be the same or different.

IPC Classes  ?

• C07F 7/08 - Compounds having one or more C—Si linkages

Abstract

Surgical resection of epileptic foci is a radical treatment, but radial surgery is inapplicable when there are foci at sites at which resection is not possible. Moreover, use of a brain cooling device requires surgical intervention and therefore inevitably poses a significant psychological barrier for patients. The present invention addresses the problem of providing a drug that can suppress or treat focal epileptic seizures without resection of epileptic foci or use of a brain cooling device. An agent for suppression or treatment of focal epileptic seizures that includes icilin as an active ingredient. The agent for suppression or treatment of focal epileptic seizures preferably contains 1.0–5.0 mM of icilin and includes a pharmaceutically acceptable additive.

IPC Classes  ?

• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61P 25/08 - AntiepilepticsAnticonvulsants
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

An object of the present invention is to provide: an anti-GPC3 antibody that recognizes an epitope different from that for existing antibodies (e.g., GC33 and GC199) and can specifically bind, even in the form of single chain antibody, to GPC3 localized on a cell membrane; CAR comprising the anti-GPC3 single chain antibody; an immunocompetent cell expressing the CAR; a gene of the anti-GPC3 antibody or a gene of the CAR; a vector comprising the anti-GPC3 antibody gene or the CAR gene; a host cell in which the vector has been introduced; a method for specifically detecting GPC3; and a kit for specifically detecting GPC3. An antibody comprising particular heavy chain CDR1 to CDR3 and particular light chain CDR1 to CDR3 defined in claim 1, and specifically binding to a human-derived GPC3 polypeptide specifically binds to GPC3 localized on a cell membrane. CAR-immunocompetent cells prepared on the basis of CAR comprising such single chain antibody are useful for cancer immunotherapy.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C07K 14/54 - Interleukins [IL]
• C07K 14/725 - T-cell receptors
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C12N 5/078 - Cells from blood or from the immune system

Abstract

An object of the present invention is to provide: an anti-GPC3 antibody that recognizes an epitope different from that for existing antibodies (e.g., GC33 and GC199) and can specifically bind, even in the form of single chain antibody, to GPC3 localized on a cell membrane; CAR comprising the anti-GPC3 single chain antibody; an immunocompetent cell expressing the CAR; a gene of the anti-GPC3 antibody or a gene of the CAR; a vector comprising the anti-GPC3 antibody gene or the CAR gene; a host cell in which the vector has been introduced; a method for specifically detecting GPC3; and a kit for specifically detecting GPC3. An antibody comprising particular heavy chain CDR1 to CDR3 and particular light chain CDR1 to CDR3 defined in claim 1, and specifically binding to a human-derived GPC3 polypeptide specifically binds to GPC3 localized on a cell membrane. CAR-immunocompetent cells prepared on the basis of CAR comprising such single chain antibody are useful for cancer immunotherapy.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C07K 14/54 - Interleukins [IL]
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C07K 14/725 - T-cell receptors
• C12N 5/078 - Cells from blood or from the immune system

Abstract

An object of the present invention is to provide CAR-expressing T cells that coexpress a chimeric antigen receptor (CAR) and a T cell immune function-enhancing factor and have a high immunity-inducing effect and antitumor activity, and to provide a CAR expression vector for the preparation of the CAR-expressing T cells. A CAR expression vector comprises a nucleic acid encoding a chimeric antigen receptor (CAR) and a nucleic acid encoding a T cell immune function-enhancing factor, wherein the nucleic acid encoding an immune function-enhancing factor is a nucleic acid encoding interleukin-7 and a nucleic acid encoding CCL19, a nucleic acid encoding a dominant negative mutant of SHP-1, or a nucleic acid encoding a dominant negative mutant of SHP-2, or a CAR-expressing T cell introduced with the CAR expression vector are prepared.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 35/26 - LymphLymph nodesThymusSpleenSplenocytesThymocytes
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/09 - Recombinant DNA-technology
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• C07K 14/52 - CytokinesLymphokinesInterferons
• C07K 14/54 - Interleukins [IL]
• C07K 14/725 - T-cell receptors
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A01K 67/00 - Rearing or breeding animals, not otherwise provided forNew or modified breeds of animals
• C07K 19/00 - Hybrid peptides
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals

Abstract

[Problem] To provide a mobile phantom system which can move with three translational degrees of freedom for reproducing an actual tumor movement and which has tracking accuracy that can be utilized to guarantee the quality of radiation therapy. [Solution] A robotic mobile body phantom system (60) includes: a robotic manipulator (61) that has three translational degrees of freedom; a robot control device (62) that controls the robot manipulator (61); a phantom (65) that is fixed to a distal end of the robot manipulator (61) and has a radiation absorptivity that is the same as that of a human body; and a mobile body tracking device (80) that measures, in real time, changes in a marker position of a patient placed near a tumor. The robot mobile body phantom system (60) is characterized in that the robot control device (62) includes a target trajectory generation unit (66) that generates a target trajectory for the robot manipulator (61) from a three-dimensional movement path of the marker position of the patient, and controls the robot manipulator (61) such that the marker position in the phantom (65) follows the target trajectory.

IPC Classes  ?

• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy
• G09B 23/28 - Models for scientific, medical, or mathematical purposes, e.g. full-sized device for demonstration purposes for medicine